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GNAO1 encephalopathy
Broadening the phenotype and evaluating treatment and outcome
ABSTRACT
Objective: To describe better the motor phenotype, molecular genetic features, and clinical
course of GNAO1-related disease.
Methods: We reviewed clinical information, video recordings, and neuroimaging of a newly iden-
tified cohort of 7 patients with de novo missense and splice site GNAO1 mutations, detected
by next-generation sequencing techniques.
Results: Patients first presented in early childhood (median age of presentation 10months, range 0–48
months), with a wide range of clinical symptoms ranging from severe motor and cognitive impairment
with marked choreoathetosis, self-injurious behavior, and epileptic encephalopathy to a milder pheno-
type, featuring moderate developmental delay associated with complex stereotypies, mainly facial
dyskinesia and mild epilepsy. Hyperkinetic movements were often exacerbated by specific triggers,
such as voluntary movement, intercurrent illnesses, emotion, and high ambient temperature, leading
to hospital admissions. Most patients were resistant to drug intervention, although tetrabenazine was
effective in partially controlling dyskinesia for 2/7patients. Emergency deepbrain stimulation (DBS)was
life saving in 1 patient, resulting in immediate clinical benefit with complete cessation of violent hyper-
kinetic movements. Five patients had well-controlled epilepsy and 1 had drug-resistant seizures. Struc-
tural brain abnormalities, including mild cerebral atrophy and corpus callosum dysgenesis, were evident
in 5 patients. One patient had a diffuse astrocytoma (WHO grade II), surgically removed at age 16.
Conclusions: Our findings support the causative role of GNAO1 mutations in an expanded spec-
trum of early-onset epilepsy and movement disorders, frequently exacerbated by specific triggers
and at times associated with self-injurious behavior. Tetrabenazine and DBSwere the most useful
treatments for dyskinesia. Neurol Genet 2017;3:e143; doi: 10.1212/NXG.0000000000000143
GLOSSARY
CK 5 creatine kinase; DBS 5 deep brain stimulation; EOEE 5 early-onset epileptic encephalopathy; EVS 5 Exome Variant
Server; ExAC 5 Exome Aggregation Consortium; GATK 5 Genome Analysis Toolkit; GPCR 5 G protein–coupled receptor;
WES 5 whole-exome sequencing; WGS 5 whole-genome sequencing.
De novo GNAO1 mutations (MIM 139311) were initially identified in children with early-
onset epileptic encephalopathy (EOEE) and severe developmental delay,1–3 with later develop-
ment of dyskinetic movement disorders1,4–6 and in children exhibiting developmental delay and
severe dyskinesia without seizures.7,8
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GNAO1 encodes a subclass (Gao) of the
Ga subunit of heterotrimeric guanine
nucleotide-binding proteins and is highly
expressed in the brain and involved in the reg-
ulation of neuronal excitability and neurotrans-
mission. Mutations in GNAO1 and other
G-protein subunits (GNAL), adenylyl cyclase
(ADCY5), cyclic nucleotide phosphodiesterase
(PDE10A), and G protein–coupled receptor
(GPCR) (GPR88)9 in early-onset movement
disorders, support the notion that disruption
of the G-protein-cAMP pathway axis is a key
contributor to the pathophysiology of dystonia
and chorea. Although the pathophysiologic
mechanisms underlying such genetic move-
ment disorders remain yet to be elucidated,
impaired modulation or transduction of trans-
membrane signaling, presynaptic autoinhibi-
tory effects, and altered neuronal excitability
are all putative disease mechanisms that might
explain the co-occurrence of multiple neuro-
logic manifestations such as epilepsy and
hyperkinesia.
Here, we report 7 newly identified patients
with GNAO1mutations, with the aim of char-
acterizing in detail the clinical phenotype,
response to treatment and outcome, as well
as associated brain MRI features.
METHODS Molecular genetic testing. Patients 1–3, 6,
and 7 were studied using whole-exome/genome (WES/
WGS) sequencing. For patient 1, WES was performed on
a SOLiD 5500XL sequencing platform (Life Technologies,
Foster City, CA). Short reads were mapped against the
GRCh37/hg19 human assembly by means of LifeScope soft-
ware (Life Technologies). Variants were detected using the
Haplotype Caller software package of the Genome Analysis
Toolkit (GATK) suite and filtered to include only variants
covered by at least 10 reads with mapping quality values
exceeding 30. For patients 2, 3, and 6, WGS was performed
with Illumina TruSeq DNA PCR-Free Sample Preparation kit
on an Illumina Hiseq 2500 sequencing platform (Illumina
Inc., San Diego, CA). For patient 3, WGS was performed as
part of the National Institute for Health Research Bioresource
Rare Disease Project. A minimum coverage of 15X (95% of
the genome) was obtained, with an average coverage of;30X.
Reads were aligned using Isaac aligner (version 01.14) (Illu-
mina Inc., Great Chesterford, UK) and mapped against the
GRCh37 hg19 human assembly. Single nucleotide variants
and insertions/deletions were identified using Isaac variant
caller. Patients 4 and 5 were studied using a Haloplex panel
(Agilent Technologies, Santa Clara, CA) of 95 epilepsy genes.
Variants were called and annotated using the GATK10 toolkit
and the ANNOVAR tool.11 Patient 7 was analyzed by WES
using Nextera Rapid Capture Exome, Illumina NextSeq
platform (Illumina Inc.) with an average coverage depth of
100–130X. An end-to-end in-house bioinformatics pipeline
including base calling, primary filtering of low-quality
reads and probable artefacts, and annotation of variants was
applied.
For all patients, variants reported as validated polymor-
phisms with a minor allele frequency .0.01 (1%) in publicly
available human variation resources (including dbSNP144,
NHLBI GO Exome Sequencing Project, UK10, 1000 Ge-
nomes, Exome Variant Server [EVS], and Exome Aggregation
Consortium [ExAC] browser) and variants present in in-house
control individuals were filtered out. In silico prediction of the
mutation pathogenicity was performed using ANNOVAR and
the dbNSFP database (v3.0a) (sites.google.com/site/jpopgen/
dbNSFP). Putative causative variants were validated by Sanger
sequencing and investigated in the probands’ parents to deter-
mine whether the mutations were inherited or had occurred
de novo.
Standard protocol approvals, registrations, and patient
consents. Written informed consent to disclose clinical infor-
mation, neuroimaging, and video footage was obtained from
all parents/guardians of the 7 participants. Informed consent
for genetic testing was obtained according to the local institu-
tional policy.
RESULTS Genetic analysis. We identified 7 patients
carrying 6 different GNAO1 (GenBank accession
number NM_020988) mutations; all the variants
occurred de novo and 4 are previously unreported
(table, figure 1).
In patient 1, we detected the novel c.139A.G
[p.(Ser47Gly)] missense variant, located in the N-
terminal domain of the protein. In patients 2 and 4,
we identified the c.625C.T [p.(Arg209Cys)] mis-
sense variant. This variant has previously been re-
ported in 1 patient with developmental delay,
intellectual disability, and severe chorea, associated
with the later onset of complex partial seizures.5 In
patient 3, we observed the novel c.72311G.A
intronic variant, and in patient 5, the novel
c.167T.C [p.(Ile56Thr)] missense variant,
located in the N-terminal domain of the protein.
In patient 6, we detected the c.118G.C
[p.(Gly40Arg)] missense mutation, located in the
N-terminal domain of the protein. A different
mutation leading to the same amino acid change
(c.118G.A [p.(Gly40Arg)]) has previously been
described in a patient with infantile-onset epi-
lepsy.3 In patient 7, we identified the novel
c.737A.G [p.(Glu246Gly)] missense variant. A
different nucleotide change in the same amino acid
position, c.736G.A [p.(Glu246Lys)], had been
reported as disease causing in patients exhibiting
developmental delay, intellectual disability, and
a paroxysmal movement disorder.5,8
The 5 missense variants are predicted to be del-
eterious using the dbNSFP database and are not re-
ported in the 1000 Genomes, ExAC, and EVS
databases. The splicing mutation c.72311G.A
was predicted to cause the loss of a splice donor site
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Table Clinical features and genetic laboratory findings
Patient/sex 1/M 2/M 3/F 4/M 5/F 6/F 7/M
Age at first
medical
evaluation/follow-
up
5 mo/5 y 5 mo Birth/10 y 8 mo 4 mo/deceased at 4 y 5 mo/5 y 6 mo 4 y/16 y 2 mo/5 y 2 mo 6 mo/15 y
GNAO1 mutation
(de novo)
c.139A.G [p.(Ser47Gly)] c.625C.T [p.
(Arg209Cys)]
c.72311G.A c.625C.T [p.
(Arg209Cys)]
c.167T.C [p.
(Ile56Thr)]
c.118G.C [p.(Gly40Arg)] c.737A.G [p.(Glu246Gly)]
Novel/reported Novel Ref. 5 Novel Ref. 5 Novel Ref. 3 Novel
Clinical findings
at follow-up
Severe ID/DD, hypotonia,
movement disorder, seizures
Severe ID/DD,
hypotonia, movement
disorder, seizures, MC
Severe ID/DD, hypotonia,
movement disorder, MC
Severe ID, focal
epilepsy, movement
disorder, MC
Mild ID, focal epilepsy,
movement disorder
Severe ID, focal epilepsy,
movement disorder, MC
Moderate-severe appendicular/
orobuccal dystonia; moderate
lower limb spasticity
Onset/type of
abnormal
movements
4 mo/severe hypotonia, mild
dystonia; 2 y 3 mo/seHypM,
dystonia; stereotypic hand
movements; SIB (lips biting, hair
pulling)
Birth/severe hypotonia;
9 y/seHypM; SIB (lips
biting)
8 mo/continuous generalized
choreoathetosis; orolingual
dyskinesia
7 mo/complex motor
stereotypies of
hands/arms;
dyskinetic motor
pattern
5 y/subcontinuous
dyskinetic tongue
movements; mild
upper limb dyskinesia
3 y/hand-to-mouth complex
stereotypies, rocking, pelvic
thrusting
6 mo/moderate hypotonia; 2 y/
moderate-severe generalized
and orobuccal dystonia, lower
limb spasticity; 7 y/seHypM
Dysphagia Yes Yes Yes No No Yes, gastrostomy Yes (progressive), gastrostomy
Head control 1 y 6 mo then regression Yes Yes Yes Yes Yes Yes
Sitting No 9 mo then regression No Yes Yes No Yes, with support
Language No No Limited No Yes No Yes, with dysarthria
Onset/epilepsy/
severity
3 y/FS with secondary
generalization/well controlled on
AED
6 y/GTCS/well
controlled on AED
No 2 y/FS/well
controlled on AED
4 y/FS/well controlled
on AED
2 mo/EOEE (OS-FS soon
followed by spasms, then FS
and GTCS)/multiple AEDs,
ketogenic diet, VNS
10 y/rare FS and GTCS/no AEDs
Interictal EEG Right frontotemporal spikes Slow background
activity
NA Bilateral
centrotemporal
spikes
Left frontotemporal
spikes
Burst suppression at onset;
slow background, multifocal
spike waves
Normal
MRI VE; thin and dysmorphic corpus
callosum; mild HyCN
VE; thin corpus
callosum; mild HyCN,
hypoplasia of inferior
vermis
VE and dilated subarachnoid
spaces; moderate cortical
atrophy; dysmorphic corpus
callosum; mild HyCN
Normal Left frontal lesion
(diffuse astrocytoma
WHO grade 2); low-
lying cerebellar tonsils
Mild VE; thin corpus
callosum
Mild loss of volume (atrophy) in
generalized distribution
Neurotransmitter
analysis in CSF
Methyltetrahydrofolate 34 nmol/L;
63–111
Methyltetrahydrofolate
66 nmol/L; 72–172
Normal Normal Normal Normal Normal
Abbreviations: AED 5 antiepileptic drugs; DD 5 developmental delay; EOEE 5 early-onset epileptic encephalopathy; FS 5 focal seizures; GTCS 5 generalized tonic-clonic seizures; HyCN 5 hypoplasia of caudate
nuclei; ID 5 intellectual disability; MC 5 microcephaly; NA 5 not available; nv 5 normal values; OS 5 Ohtahara syndrome; seHypM 5 severe exacerbation of hyperkinetic movements; SIB 5 self-injurious behavior;
VE 5 ventricular enlargement; VNS 5 vagus nerve stimulation.
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using Mutation Taster and Berkeley Drosophila
Genome Project.
Clinical features and neurologic investigations. Clinical
features, as obtained by history taking, direct
clinical examination, and evaluation of video foot-
age, neuroimaging, and genetic findings are de-
tailed in the table, in figure 2 and in videos 1–5
at Neurology.org/ng. Within the cohort, we iden-
tified 4 boys and 3 girls. Six of the patients are alive,
currently aged 5–16 years.
The onset of abnormal hyperkinetic movements
ranged from 4 months to 9 years of age (median 2
years). Within the cohort, there was considerable clin-
ical heterogeneity with regard to motor semiology and
severity. Profound hypotonia preceded the onset of
abnormal movements in patients 1, 2, and 7, who
later developed dystonia, followed by severe episodes
of paroxysmal choreoathetosis. Gradual development
of facial dyskinesia was also reported in these patients
(videos 1, 2, and 5). Patient 3 experienced continuous
generalized choreoathetosis and facial dyskinesia. At
the age of 4, because of repeated and prolonged infec-
tive episodes, status dystonicus developed, requiring
intensive care, with sedation, ventilation, tracheos-
tomy, gastrostomy, and metabolic support. MRI
showed progressive cerebral atrophy. Status dystoni-
cus persisted, with rise in creatine kinase (CK) and
renal failure, leading to multisystemic deterioration
and death. Patient 4 exhibited complex motor stereo-
typies and a dyskinetic motor pattern (video 3).
Patient 5 manifested almost continuous orolingual
dyskinesia. She also had mild dyskinetic movements
of the upper limbs (video 4). Patient 6 exhibited com-
plex rocking, staring, back arching, and pelvic thrust-
ing movements, associated with hand-to-mouth
complex stereotypies.
Several triggers were reported to elicit or exacer-
bate abnormal movements, including emotion (all pa-
tients), intercurrent illnesses (patients 1, 2, and 7),
Figure 1 Membrane topology modeling of GNAO1
Membrane topology was predicted using the Protter online tool29 (P09471, GNAO_HUMAN). Known GNAO1missense mutations are indicated in green, the
deletion is in yellow. Mutations found in this report and already described in the literature are indicated in light blue, novel mutations in red.
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high temperature (patient 1), intention, and purpose-
ful movements (patients 1 and 7). Attacks frequently
presented in clusters, lasting minutes (patient 1),
hours or weeks (patient 2), or months (patient 7)
(videos 1, 2, and 5). Such exacerbations were pharma-
coresistant to standard therapies. Patients 1, 2, and 7
also exhibited associated autonomic instability, sweat-
ing, dehydration, and rise in CK, frequently requiring
hospitalization and intensive care and, often, admin-
istration of anesthetic agents (patients 2 and 7).
Worsening of baseline dystonia with hyperkinetic
movements and loss of fine motor skills were reported
in patient 7 after each episode. One such exacerbation
determined a 3-month admission to the intensive care
unit and anesthetic agents. The emergency placement
of a deep brain stimulator (DBS) device bilaterally
into the globus pallidus interna was transformative
and resulted in almost complete remission of the pro-
nounced hyperkinesia, although residual generalized
dystonia persisted.
Six patients (1, 2, 4–7) exhibited epilepsy, with
age of seizure onset ranging from 2 months to 10
years. While seizures were well controlled by medica-
tion in 4 patients, patient 7 presented rare generalized
tonic-clonic seizures and focal dyscognitive seizures
and patient 6 had a history of EOEE followed by
drug-resistant focal epilepsy with dyscognitive seiz-
ures. Patient 3 never had seizures and died at age 4
years.
Additional clinical features were also reported in
some patients. Patients 1 and 2 exhibited mild self-
injurious behavior (lip biting, hair pulling). Patient
7 has a history of significant anxiety, requiring treat-
ment with fluoxetine, sertraline, and risperidone.
Figure 2 MRI characteristics of 7 patients with GNAO1 mutations
For patients 1–6, a set of 3 images including an axial (A, D, G, J, M, and S), coronal (B, E, H, K, N, and T), and sagittal midline (C, F, I, L, O, and U) sequences is
shown. For patient 5, in addition, 1 axial (P) and 2 coronal (Q and R) images are shown to illustrate better the neoplastic lesion in the left frontal lobe (arrows).
For patient 7, axial images of 2 different investigations (V and W) and a sagittal image are shown to illustrate better the progression of atrophic changes.
Images are at 1.5–3T. Images A–E, G, J, K, N, O, Q, S, T, andW are T2weighted. Images F, I, L, U, and X are T1weighted. Images H, M, P, and R are acquired as
fluid attenuation inversion recovery (FLAIR) sequences. Patient 1: axial and coronal images show mild ventricular enlargement in the frontal horns, with
concomitant hypoplasia of the caudate nuclei. The sagittal section shows a thin corpus callosum. Patient 2: axial and coronal images show mild ventricular
enlargement in the frontal horns, with mild hypoplasia of the caudate nuclei, likewise seen in patient 1. The sagittal section shows a thin corpus callosum and
a hypoplastic inferior vermis. Patient 3: axial and coronal images showmoderate cortical atrophy, with ventricular enlargement and small caudate nuclei. The
sagittal image shows a dysmorphic corpus callosum. Patient 4: no structural abnormality is visible on MRI. Patient 5: MRI shows an isolated abnormality
(arrows) involving the anterolateral aspect of the left frontal lobe, including the cortex and underlying whitematter, with increased signal intensity on both T2
and FLAIR images. Histopathology, after surgical removal of the lesion, showed characteristics consistent with a diffuse astrocytoma (WHOgrade 2). Patient
6: axial and coronal images show dilated lateral ventricles; the sagittal cut shows a thin corpus callosum. Patient 7: the first axial MRI at age 2 (V) is normal,
but a follow-up study at age 16 (W) shows loss of brain volume in generalized distribution. No abnormalities in the brainstem and cerebellum are visible in the
sagittal image at age 16 (X).
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In our cohort, diagnostic metabolic investigations
were unremarkable, including CSF neurotrans-
mitters, except for the reduction of CSF
5-methyltetrahydrofolate levels in patients 1 and 2.
In both patients, calcium folinate administration
was started but did not lead to discernible clinical
improvement. Brain MRI (figure 2) was unremark-
able in patients 4 and 7, while inconsistent changes
were detected in the remaining patients (microceph-
aly, macrocephaly, progressive cerebral atrophy with
dilated ventricles and subarachnoid spaces, caudate
volume loss, and dysmorphic corpus callosum). In 1
patient (patient 5), a focal lesion involving the gray
and white matter of the left frontal lobe was identified
and confirmed as a diffuse astrocytoma (WHO grade
2) after surgical removal.
DISCUSSION Through its activation by GPCRs,
Gao is involved as a modulator or transducer in
several transmembrane signaling pathways.10,12,13
Gao also mediates the widespread presynaptic auto-
inhibitory effect of many neurotransmitters (via a2
adrenoreceptors, M2/M4 muscarinic, m/d opioid,
GABAB, adenosine A1, or endocannabinoid CB1
receptors) through a reduction of sensitivity to
membrane depolarization and a direct inhibitory
effect on the vesicle fusion process.14 Furthermore,
Gao indirectly activates G protein–coupled
inwardly rectifying K1 channels that mediate
neuronal excitability through a slower self-
inhibitory postsynaptic potential.15
Gao-deficient mice (Gnao12/2) have occasional
seizures, severe impairment of motor-control, hyper-
algesia, and behavioral abnormalities with early post-
natal lethality.16,17 Although heterozygous Gnao1
knockout mice do not manifest seizures, a gain-of-
function knock-in mutant murine model (Gnao1
Gly184Ser/1) has severe seizures with markedly
increased frequency of interictal epileptiform dis-
charges and sudden premature death. Animal model
data thus suggest that pathogenic monoallelic
GNAO1 mutations in humans may also result in
a gain-of-function effect. Moreover, impaired protein
localization and decreased GNAO1-mediated inhibi-
tion of calcium currents by norepinephrine compared
to the wild type have been showed in in vitro func-
tional expression systems.18 GNAO1 has also been
implicated in the etiology of brain tumors, such as
ependymoma and glioblastoma multiforme.19,20
De novo GNAO1 mutations were originally first
reported in Ohtahara syndrome and EOEE in 4
children, associated with abnormal movements in
2.1 Since this initial description, 30 additional pa-
tients have been reported with an emerging pheno-
type characterized by neurodevelopmental delay
with an early onset of a hyperkinetic movement
disorder, inconsistently associated with epilepsy.
The epilepsy phenotype of the 7 patients we studied
ranged from EOEE to mild drug-sensitive epilepsy,
whose onset could precede or follow that of the
movement disorder, which was certainly a promi-
nent feature. The occurrence of stereotypies (pre-
viously reported in 2 patients with EOEE)4,5 and
characteristic paroxysmal exacerbations, associated
often with clear triggers, may both be considered
as 2 further important discerning clinical features
of GNAO1 encephalopathy.
As previously reported, standard investigations
appear to be unyielding in patients with GNAO1-
related disease. Two of our patients had low levels
of CSF 5-methyltetrahydrofolate, although this was
not consistently seen in the cohort. Brain MRI (figure
2) showed a combination of minor features in most,
including a thin corpus callosum with dilated ven-
tricles in 4, as previously reported8 as well as hypo-
plastic caudate nuclei in 3 and a diffuse astrocytoma
(WHO grade II) in the oldest patient (patient 5). The
latter finding raises concerns about the possible role of
the Gly40Arg mutation in tumorigenesis, in view of
the reported role of GNAO1 in promoting oncogenic
transformation.19,21 A somatic GNAO1 mutation
(p.Arg243Hys) has been identified in breast carcino-
mas where it promotes oncogenic transformation by
rendering the Ga subunit constitutively activated and
enhancing signaling pathways responsible for neo-
plastic transformation.21 Although GNAO1 was iden-
tified as part of the human plasma proteome, its high
abundance was suggested to promote cancer cell via-
bility via proapoptotic protein interference.20 Larger
series and longer follow-up data will be fundamental
to determine whether patients carrying specific
GNAO1 mutations are at higher risk of developing
tumors.
TwentyGNAO1mutations, 19missense and 1 dele-
tion, have been previously reported (figure 1).1–8,22–28
The only reported deletion was described in a patient
with a severe phenotype, including Ohtahara syn-
drome, developmental delay, and severe intellectual
disability, who died secondary to respiratory-tract
complications.1 The 7 patients we are reporting har-
bored 6 different mutations, one of which was evi-
dent in 2 patients (figure 1). Two of the 6 mutations
have been reported previously [p.(Arg209Cys) and
p.(Gly40Arg)],3,5 while 4 are novel [p.(Ser47Gly),
c.72311G.A, p.(Ile56Thr), and p.(Glu246Gly)].
The c.72311G.A splicing mutation, likely result-
ing in abnormal mRNA splicing, was found in
patient 3, who died at 4 years of age and exhibited
the most severe phenotype. The p.(Arg209Cys)
mutation falls within the switch II domain, which
is important for guanidine nucleotide-dependent
regulation of downstream effectors and is highly
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conserved across vertebrate species.5 The Arg209
amino acidic residue represents a mutation hotspot
since, including our series, 10 patients carrying muta-
tions affecting this residue have been reported. All
these patients presented developmental delay and cho-
rea or dystonia and 3 had seizures. The p.(Glu246Gly)
mutation, although novel, affects an amino acid resi-
due that represents a second mutation hotspot since 7
patients with mutations affecting this residue have
been reported (including our own), all presenting with
developmental delay and chorea, with only patient 7
developing late childhood–onset seizures. The Arg209
and Glu246 residues form a salt bridge that is
important for the stabilization of the Ga-containing
complexes, mainly in GTP-bound active state.5
Hence, the variants involving these residues should
disrupt their interaction, resulting in destabilization
of the Ga-containing complexes.5 In our study, the
identification of 2 additional patients harboring
mutations involving the Arg209 amino acid residue
and 1 additional patient harboring a mutation involv-
ing the Glu246 amino acid residue confirm that these
residues are GNAO1 mutation hotspots.
Tetrabenazine was the most effective drug in the
baseline management of the severe involuntary move-
ments in patients 1 and 7; its positive effect was pre-
viously described in 6 patients8 treated in association
with neuroleptics (risperidone and haloperidol). In
addition, a recently reported patient harboring the
c.626G.A (p.Arg209His) exhibited an initial signif-
icant improvement with tetrabenazine and subse-
quent response to trihexyphenidyl.28 Emergency
DBS, during a severe prolonged exacerbation, was life
saving in patient 7. Three patients with GNAO1 mu-
tations had previously been reported whose hyperki-
netic exacerbations, usually preceded by illness,
clearly improved after DBS insertion into the globus
pallidus.7,27 Our report provides further evidence that
DBS should be promptly considered in all the pa-
tients with sustained intractable movement disorder
due to GNAO1 mutations.
Long-term outcome of early-onset GNAO1-
related disease remains yet to be determined. We
would suggest that prognosis of these patients should
remain guarded, as 3 previously reported patients1,8
and 1 in this series have died in childhood. Further-
more, 2 reported patients have experienced definite
motor regression in the early stages of disease.7,8
Identification of more patients will certainly aid
delineating this newly identified disorder. Given
the ever-growing disease spectrum, GNAO1 muta-
tions should be considered in the differential diagno-
sis for patients with unexplained paroxysmal/
nonparoxysmal early-onset hyperkinetic movement
disorders, especially in the context of neurodevelop-
mental delay with or without epilepsy.
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